Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Dose-dependent weight reduction; highest-dose groups produced very large mean reductions over 48 weeks.
What this study tells us
Participants were assigned to comparison groups by chance, usually with placebo and/or blinding to reduce bias. This is a strong design for testing cause and effect, but the population, duration and endpoints still limit what can be concluded.
Adults with obesity or overweight plus a weight-related condition
n=338
Dose-dependent weight reduction; highest-dose groups produced very large mean reductions over 48 weeks.
Phase 2 duration; investigational product; no long-term outcomes; cross-trial comparisons are inappropriate.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
Dose-dependent weight reduction; highest-dose groups produced very large mean reductions over 48 weeks.